The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT” or the “Company”), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, has announced the appointment of Praveen Tipirneni, MD, to its Board of Directors as a non-executive director. Dr. Tipirneni most recently served as President and CEO of Morphic Therapeutics Inc. from company founding until the acquisition by Eli Lilly for $3.2 billion, and brings a wealth of industry experience and expertise to BBOT’s Board.

Prior to founding Morphic, Dr. Tipirneni served as Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals from 2006 until the company’s acquisition by Merck in 2015 for approximately $9 billion. He also served as a 1st Lieutenant in the U.S. Army. Dr. Tipirneni received a BS degree from Massachusetts Institute of Technology (MIT) in Mechanical Engineering and an MD from McGill University. After completing his post-graduate residency in Internal Medicine at the University of Illinois, Chicago, he received his MBA in Healthcare Finance from the University of Pennsylvania’s Wharton School of Business.

“I am excited to join the Board of BBOT,” said Dr. Tipirneni. “The science and people there are truly first-class, and I look forward to helping them advance and develop their pipeline.”

Frank McCormick, PhD, Chairman of BBOT’s Board added, “I am delighted to welcome Praveen to BBOT. His deep expertise in biotechnology research and development will be instrumental to helping us execute our near- and long-term strategy to deliver superior results for patients, employees, and investors.”

About TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information visit bridgebiooncology.com.

Contacts

BridgeBio Oncology Therapeutics (BBOT) Contact:

Idan Elmelech

Senior Vice President, Strategy & Business Development

Contact@bridgebiooncology.com

(650) 405-7021

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.